“At Intra-Cellular Therapies, we understand the lifelong debilitating struggle people with schizophrenia experience. The need for new treatment options for this community has driven our efforts to ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. In a statistically ...

Caplyta is prescribed for adults to treat schizophrenia, depression related to bipolar I or II disorder, and as an add-on treatment with antidepressants for major depressive disorder (MDD) Caplyta ...

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

The FDA is making a habit of delivering Intra-Cellular Therapies an early Christmas present. Two years ago, on Dec. 23, the U.S. regulator approved Intra-Cellular’s first product, Caplyta, for ...

“We are encouraged by CAPLYTA's strong growth trajectory in the third quarter and look forward to further growth in the remainder of 2024 and beyond. We are on track to submit our sNDA for the ...

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, has been garnering significant attention from ...